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Although DNA methylation is required for mammalian
development, the presence of 5-methylcytosine can ren-
der the nuclear genome unstable, leading both to heri-
table point mutations and to somatic events that cul-
minate in cancers. This instability probably arises
through several distinct mechanisms, some of which are
only beginning to come to light. DNA-methylation pat-
terns are remarkably plastic during development, show-
ing clear differences in sperm and oocyte, followed by
genomewide demethylation before a wave of de novo
methylation establishes the adult pattern (Razin and
Shemer 1995). In general, CpG-rich regions of DNA,
termed “CpG islands,” remain unmethylated through-
out this time, with the exception of those regions as-
sociated with either imprinted genes or the promoters
of genes located on the inactive X chromosome in fe-
males (Bird 1986). The biochemical mechanisms re-
sponsible for these dynamic changes are almost com-
pletely unknown, but methylation patterns are the same
in different individuals (Achten et al. 1991), and they
show strong exclusion of methylation from CpG islands.
In contrast, the patterns are almost always altered in
human cancers, with inappropriate CpG-island meth-
ylation being common (Jones and Gonzalgo 1997). Be-
cause genomic instability is a hallmark of human cancer,
recent work in the field of DNA methylation has focused
on the potential both for this process to create point
mutations and chromosomal aberrations and for alter-
ations in the DNA-repair machinery to change DNA-
methylation patterns.
CpG Sites as Mutational Hotspots in Somatic Cells
CpG sites are widely recognized as hotspots for mu-
tations in the germ line, where they contribute to ∼30%
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of all point mutations (Cooper and Youssoufian 1988).
In addition, CpG sites in the coding regions of tumor-
suppressor genes are strong hotspots for acquired so-
matic mutations leading to cancer (Greenblatt et al.
1994). The CpG sites in the p53 coding region are meth-
ylated in all human tissues studied (Magewu and Jones
1994) and contribute to as many as 50% of all inacti-
vating mutations in colon cancer and to as many as 25%
of all inactivating mutations in cancers in general
(Greenblatt et al. 1994). One hotspot, located at codon
248, is frequently mutated in both colon cancer and lung
cancer. Here, however, the mutation is not the familiar
CrT transition but, rather, a GrT transversion possibly
due to preferential binding of benzo[a]pyrene diepoxide
to the target guanine. In a fascinating recent study, Den-
issenko et al. (1996) showed that the presence of 5-
methylcytosine at the CpG site actually increased the
formation of the adduct at guanine, thus providing an-
other biochemical pathway leading to somatic mutation.
The mechanism responsible for the increased muta-
bility of 5-methylcytosine relative to cytosine has been
known for some time. The pioneering work of Coulon-
dre et al. (1978) established the base as a hotspot in
Escherichia coli, and they proposed that this hotspot is
due to difficulties inherent in the repair of T:G mis-
matches resulting from cytosine deamination in DNA
(Coulondre et al. 1978). Figure 1 shows that there are
three major variables involved in the fixation of these
mutations: the rate of deamination, the rate of repair,
and the rate of cell division. Because of the remarkable
prevalence of CrT transition mutations in p53 in human
cancers, we and others have investigated whether any
of these variables is altered in cancer cells. The rate of
deamination is probably constant, since (1) it is caused
by a simple chemical reaction and (2) the rate is more
than sufficient to account for all the mutations observed
in double-stranded DNA (Shen et al. 1994). Alterations
in the presumed major repair pathway catalyzed by thy-
mine DNA glycolyase (TDG) do not seem to be com-
mon, since (a) we found no evidence for decreased en-
zymatic activity in colon tumors and (b) mutations in
TDG have not been found (Schmutte et al. 1996). The
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Figure 1 Pathways for the formation of signature CrT muta-
tions at methylated CpG sites in mammalian cells. 5-Methylcytosine
hydrolytically deaminates at a constant rate to form T:G mispairs
(boxed). These mispairs are presumably repaired by the TDG enzyme
(Schmutte et al. 1996). Unrepaired mispairs are fixed as CrT tran-
sitions if cell division occurs before repair is complete. Since the de-
amination rate is constant and alterations in the TDG-repair pathway
have not been found, variations in the rate of cell division are most
likely primarily responsible for mutation fixation.
prevalence of mutations is probably therefore a reflec-
tion of an increased rate of division (Lieb and Rehmat
1997). Indeed, CpG mutations are more common in
those cancers where cell division is elicited by factors
such as hormonal stimulation or repair of tissue damage
after chronic stimulation (Greenblatt et al. 1994). The
mutational pressure of 5-methylcytosine in the germ line
is therefore also apparent in somatic cells. Once inac-
tivating mutations occur in key genes such as p53, other
alterations may follow, including substantial changes in
methylation patterns and the silencing of other regula-
tory genes.
The Methylation Machinery
DNA methylation, the covalent addition of a methyl
group to the C-5 position of cytosine in the context of
the CpG dinucleotide, is mediated by the DNA meth-
yltransferase enzyme. This large enzyme (∼200 kD) dis-
plays a marked preference for hemimethylated DNA,
DNA that carries a methyl-cytosine on one strand (Bes-
tor and Verdine 1994). Hence, it had been proposed that
this enzyme’s primary function is to maintain the meth-
ylation patterns laid down during development, and it
is often referred to as the “maintenance” methlytrans-
ferase. This methyltransferase will copy the preexisting
pattern of methylation, from the original parental strand
to the newly synthesized daughter strand, after each
round of DNA synthesis. The mechanism by which this
copying is performed is rather unusual. The target cy-
tosine is extruded from the double helix into the active-
site cleft in the enzyme (Klimasauskas et al. 1994).
There, the now extrahelical cytosine is attacked by a
conserved active-site cysteine (Bestor and Verdine 1994),
followed by transfer of a methyl group from the cofactor
S-adenosyl-L-methionine (SAM) to the 5 position (Smith
et al. 1992).
Is all of the DNA methylation at CpG accomplished
by a single enzyme? To date, only the maintenance meth-
yltransferase has been cloned and characterized. How-
ever, this enzyme does not appear to be well suited for
the task of de novo methylation, because of its preference
for hemimethylated DNA, and a developmentally reg-
ulated de novo methyltransferase has been postulated.
Proteolytic removal of the regulatory domain of the
maintenance methyltransferase results in an increase in
de novo methylation ability in vitro; such processing has
not been observed in vivo, however (Bestor and Verdine
1994). Recently, compelling evidence for the existence
of an independently encoded de novo methyltransferase
has come to light. Mice bearing a null mutation of the
known methyltransferase gene showed arrested devel-
opment prior to the 8-somite stage but contained low
but stable levels of cytosine methylation (Lei et al. 1996).
Embryonic stem (ES) cells used for the creation of the
knockout mice are viable, indicating that methylation
may be essential only in differentiated cells (Lei et al.
1996). Retroviral infection of methyltransferase-null ES
cells leads to de novo methylation of proviral DNA, as
observed in normal ES cells, presumably a defense mech-
anism against invading parasitic sequences (Bestor and
Coxon 1993; Lei et al. 1996). This de novo methyl-
transferase is then thought to be down-regulated during
differentiation, once the desired methylation pattern has
been established. This pattern is then propagated by the
maintenance methyltransferase for the life of the organ-
ism. Validation of this idea, however, will await cloning
and characterization of this de novo enzyme.
Methylation Changes in Cancer
As with the demethylation and de novo methylation
observed during development, changes in methylation
patterns during neoplasia have been recognized for some
time (Counts and Goodman 1995). Initially it was
shown that malignant cells have lower levels of meth-
ylation than do normal cells (Feinberg et al. 1988). This
global hypomethylation accompanies a hypermethyla-
tion of CpG islands, DNA regions often associated with
promoters of human genes that are normally protected
from methylation (Bird 1986). The mechanism by which
these regions remain unmethylated in the normal cell is
not known, but it may be mediated by the binding of
certain transcription factors. In malignant cells, these
CpG-island regions become methylated and expression
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of the associated gene is silenced (Counts and Goodman
1995). In the case of a tumor-suppressor gene, this may
result in a growth advantage for the cell. DNA meth-
ylation–mediated transcriptional inhibition has thus
been proposed as a mechanism that is alternative to mu-
tation and deletion, in the removal of tumor suppres-
sor–gene function (Jones 1996). Examples of such genes
include the two cell-cycle regulators p16 Ink4a (Gon-
zalez-Zulueta et al. 1995) and p15 Ink4b (Herman et
al. 1996), the von Hippel–Lindau gene VHL in some
renal carcinomas (Herman et al. 1994), the retinoblas-
toma gene product Rb (Stirzaker et al. 1997), BRCA1
(Dobrovic and Simpfendorfer 1997), the angiogenesis
inhibitor thrombospondin (Ahuja et al. 1997), and the
metastasis-suppressor gene E-cadherin (Graff et al.
1995).
In a recent issue of Science, a report by Chuang et al.
(1997) has shed new light on how methylation patterns
are maintained and how they may become altered in
cancer. It was shown that the DNA methyltransferase is
targeted to newly replicated DNA by the replication-
associated protein PCNA (proliferating cell nuclear an-
tigen). PCNA is the polymerase-processivity factor for
the d and e DNA polymerases, is homologous to the E.
coli b subunit, and is required for DNA replication
(Krishna et al. 1994). PCNA is also the target of the
cell-cycle regulator p21WAF1/CIP1 (Waga et al. 1994). The
binding of p21 and DNA methyltransferase to PCNA
appears to be mutually exclusive, since their levels have
been shown to be inversely related in both normal and
transformed cells (Chuang et al. 1997). In response to
DNA damage, p53 is up-regulated, leading to increased
synthesis of p21 (El-Deiry et al. 1993). p21 binding to
PCNA then inhibits DNA synthesis and thus mediates
the ability of p53 to arrest cell division (Waga et al.
1994). Targeting of the DNA methyltransferase to
PCNA may then allow for the rapid remethylation of
newly synthesized daughter strands before being pack-
aged into chromatin. This may be important, since one
of the principle chromatin-organizing proteins, histone
HI, has been shown to inhibit DNA methylation (Carotti
et al. 1996); thus this tight spatial and temporal linkage
of DNA methylation and DNA synthesis may be
essential.
In either a malignant cell or a premalignant cell, how-
ever, p53 function is very often lost (Vogelstein and Kinz-
ler 1992), sometimes as a result of point mutations in
CpG dinucleotides (Greenblatt et al. 1994; Magewu and
Jones 1994). Thus, loss of p21 is also a common event
in cancer. One might then propose that loss of p21 would
perturb a balance between the p21 and DNA-methyl-
transferase interaction with PCNA, which would allow
for an increase in methylation errors (fig. 2), as we have
proposed elsewhere (Jones 1996). For example, DNA
methyltransferase has an affinity for certain forms of
damaged DNA (Smith et al. 1994). PCNA is required
for both mismatch repair (Umar et al. 1996) and nu-
cleotide-excision repair (Nichols and Sancar 1992). Loss
of p21, which also associates with PCNA at sites of DNA
repair, might then grant greater access of the DNA meth-
yltransferase to these regions, resulting either in a meth-
ylation error or in de novo methylation at a CpG site
that is not normally methylated. This type of random
methylation error will then be propagated and may act
as a nucleus for other such events, leading, over time,
to the type of inappropriate de novo methylation seen
in cancer cells and to the transcriptional silencing of key
tumor-suppressor genes (fig. 2).
DNA Methylation and DNA Repair
Another interesting corollary to the relationship be-
tween DNA methylation and DNA repair comes from
two recent papers. The first, by Kane et al. (1997),
showed for the first time that the genes coding for mis-
match-repair proteins may themselves be subject to
methylation-mediated transcriptional silencing. The
hMLH1 promoter was found to be methylated in certain
sporadic colon tumors and tumor cell lines that failed
to express hMLH1—but in which no coding-sequence
mutation was detected. Understanding of both the im-
portance and the frequency of this mode of inactivation
of the mismatch-repair pathway will have to await clon-
ing and characterization of the promoter regions of other
mismatch-repair genes. The second paper, by Lengauer
et al. (1997), describes an interesting phenomenon, in
which retroviral infection of mismatch repair–deficient
cell lines led to de novo methylation of and transcrip-
tional silencing of the proviral DNA whereas mismatch
repair–proficient cell lines were competent to express
the retrovirally encoded reporter gene. Another recent
study has also noted methylation-pattern differences be-
tween mismatch repair–deficient and mismatch re-
pair–proficient cell lines (Ahuja et al. 1997). In light of
the results of Chuang et. al. (1997), these effects may
result from the interaction of the DNA methyltransferase
with PCNA. PCNA associates with the mismatch-repair
proteins MLH1 and MSH2 in yeast, and PCNA is re-
quired for efficient mismatch repair. Furthermore, the
presence of PCNA appears to be required at a step pre-
ceding DNA resynthesis, so PCNA may not simply be
acting as a polymerase-accessory factor (Umar et al.
1996). Loss of p21 from sites of DNA repair, by inac-
tivation of p53, may also perturb a balance between
various interacting repair proteins, leading to aberrant
DNA methylation. Increased cell division, due to the loss
of the cell-cycle inhibitor p21, would then allow these
mutations and methylation changes to become fixed in
the genome, as indicated in figure 2.
The role for DNA methylation in causing somatic mu-
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Figure 2 Pathways for the formation of methylation errors and mutations in cancer cells, and the central role of PCNA. In a normal cell
(A), some interplay between p21 and the DNA methyltransferase (DNA-MT) allows for DNA replication and maintenance methylation (Chuang
et al. 1997). Typically, cytosines in isolated CpG dinucleotides are methylated (blackened lollipops), but those in CpG islands are not methylated
(unblackened lollipops). In a malignant cell (B), the loss of p21 perturbs the balance and allows for methylation errors to occur and for these
to become fixed, potentially leading to inactivation of tumor-suppressor genes. In a normal cell (C), the DNA methyltransferase may be excluded
from a site of damage (indicated by “#”) by p21, allowing repair to be completed by mismatch repair (MLH1 and MSH2) or nucleotide
excision repair (NER). In a malignant cell (D), the loss of p21 may allow the methyltransferase access to sites of DNA damage, causing
methylation errors because of its affinity for abnormal or damaged DNA structures (Smith et al. 1994). Furthermore, we suggest that the repair
pathways themselves may be affected by both the loss of p21 and the presence of the methyltransferase, which may increase the error rate
(indicated by “?”).
tations is firmly established. Recent evidence—such as
the finding of (1) de novo methylation of a mismatch-
repair gene in cancer and (2) linkage between the DNA
methyltransferase and PCNA, a critical protein involved
in both DNA replication and repair—even suggests that
methylation and genomic instability may be linked. The
role of DNA damage in the alteration of patterns of
DNA methylation, due to the requirement for PCNA in
both mismatch repair and nucleotide-excision repair and
to the association of PCNA with the DNA methyltrans-
ferase, is an exciting new idea that will no doubt be a
major focus of research in the field in coming years.
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